Supplements

A multimodal personalised precision geromedicine intervention improves muscle strength, immune function, and cognitive performance in middle-aged-to-older adults

The PROMETHEUS protocol tests an 8-week multimodal intervention including sleep and dietary recommendations, supplements, exercise, and cognitive therapy in 20 middle-aged-to-older participants. Primary outcomes measure muscle strength and mass, immune function, and cognitive performance, with feasibility indicators such as adherence and trial completion. The study aims to inform a subsequent 12-month randomised controlled trial.

Last updated: Jul 8, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.

observational

Kuerec AH, Guan L, Wang W, Barros D, Alenezi WM, Grgic J, Wazny VK, Morwani-Mangnani J, Dotou M, Zhang D, Chen T, Wang J, Ong JYY, Tay JH, To-Anan N, Sotelo CR, Khan ADBN, Bruggink W, Nair SV, Sukor SABM, Rikka S, Sin RCY, Chong HM, Hashim FBM, Hameed SNBS, Hamid ABBA, Jin X, Fuster C, Chen Y, Milani A, Zhang C, Macary P, Singham TR, Sachaphibulkij K, Dunn M, Yi L, Maier AB · GeroScience (2026)

Participants: N/A
Duration: 8 weeks
Intervention: Multimodal intervention including fundamental components (sleep and dietary recommendations; whey protein, creatine, and fucoidan supplementation; supervised exergaming dual-task cognitive-physical training; motivational interviewing; cognitive behavioural therapy) and augmented personalised components (urolithin A, nicotinamide mononucleotide, multivitamin-multimineral based on baseline gerotypes; mid-intervention adjustments including ergothioneine for cognition)
Outcome: Muscle strength and mass, immune function, cognitive performance, feasibility indicators (adherence, trial completion), secondary biological/clinical/digital biomarkers of ageing, qualitative motivation and personal values
Effect Size: N/A
Population: 20 middle-aged-to-older participants (age not further specified in abstract)

Result:

PubMed: 42393428DOI: 10.1007/s11357-026-02394-6

Mechanism Graph

Personalised baseline gerotype assessment identifies individual ageing patterns
↓
Fundamental multimodal interventions target multiple ageing pathways
↓
Augmented interventions (urolithin A, NMN, multivitamin) added based on muscle, VO2peak, and cognition
↓
Mid-intervention adjustments (dose escalation, ergothioneine) based on individual response
↓
Result: Potential improvement in muscle strength, immune function, and cognitive performance

Limitations

  • ⚠Small sample size (n=20) limits generalisability
  • ⚠No control group; feasibility study design precludes causal inference
  • ⚠Short 8-week duration may not capture long-term ageing outcomes

Frequently Asked Questions

What is the PROMETHEUS study?▼

It is an 8-week feasibility and exploratory study testing a multimodal personalised intervention for healthy ageing in 20 middle-aged-to-older adults, part of the XPRIZE healthspan competition.

What interventions are included in the PROMETHEUS protocol?▼

Fundamental interventions include sleep and dietary advice, whey protein, creatine, and fucoidan supplements, supervised exergaming, motivational interviewing, and cognitive behavioural therapy. Augmented interventions are personalised based on gerotypes and include urolithin A, nicotinamide mononucleotide, multivitamin-multimineral, and ergothioneine.

What are the primary outcomes measured?▼

Primary outcomes are muscle strength and mass, immune function, cognitive performance, and feasibility indicators like adherence and trial completion.

What is the significance of this study?▼

It aims to demonstrate feasibility and explore outcome trajectories for a personalised precision geromedicine approach, informing a future 12-month randomised controlled trial.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Kuerec AH, Guan L, Wang W, Barros D, Alenezi WM, Grgic J, Wazny VK, Morwani-Mangnani J, Dotou M, Zhang D, Chen T, Wang J, Ong JYY, Tay JH, To-Anan N, Sotelo CR, Khan ADBN, Bruggink W, Nair SV, Sukor SABM, Rikka S, Sin RCY, Chong HM, Hashim FBM, Hameed SNBS, Hamid ABBA, Jin X, Fuster C, Chen Y, Milani A, Zhang C, Macary P, Singham TR, Sachaphibulkij K, Dunn M, Yi L, Maier AB. "PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.." GeroScience, 2026. PMID: 42393428 DOI: 10.1007/s11357-026-02394-6
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.